On May 14, 2026, Siren Fund disclosed a new position in Veradermics (MANE). Based on the quarterly average price, the fund invested approximately $75.94 million to acquire 1,505,374 shares. The position’s quarter-end value was $95.06 million, reflecting the share purchases and subsequent price movements.
As of May 13, 2026, Veradermics’ stock price was $107.14, an increase of more than 500% from its February IPO price of $17. As of the market close on May 14, 2026, the company had a market capitalization of $4.43 billion and a net loss of $70 million over the trailing twelve months.
Veradermics develops therapies in dermatology and aesthetics, including an oral drug for treating androgenetic alopecia, a dissolvable microneedle patch for wart immunotherapy, and therapies for alopecia areata and molluscum contagiosum. The company operates a research-driven biopharmaceutical model, generating potential revenue through proprietary drug candidates that address both adult and pediatric dermatology markets. Its services target medical providers, clinicians, and researchers in the fields of dermatology and aesthetic medicine.
Since Veradermics went public in February, its stock has soared. Siren Fund’s willingness to establish such a large position suggests that investors are increasingly confident that the company’s leading hair loss treatment has the potential to develop into an impactful, mass-market product.
Market enthusiasm stems in part from recently released Phase 2/3 data on VDPHL01, an oral extended-release minoxidil for treating androgenetic alopecia. Veradermics stated that the study demonstrated “early, sustained, and robust” hair growth results, with a safety profile comparable to placebo. Company management believes the drug has the potential to become the first FDA-approved oral treatment for androgenetic alopecia in nearly 30 years.
Veradermics raised approximately $766.8 million this year through its IPO and subsequent financing activities, and management expects existing funds to support the company’s operations through 2030. Additional Phase 3 data involving more than 1,000 male patients is expected later this year.
Ultimately, Veradermics occupies a compelling market position for investors. Of course, the risk is that the stock’s substantial post-IPO rally has already priced in a great deal of optimistic expectations, while key data has yet to be fully released.
Veradermics has attracted strong capital market attention with its breakthrough drug candidate in the hair loss treatment space. Siren Fund’s heavy position further confirms the investment enthusiasm in this arena. However, the company remains in a loss-making state, and its stock price has already priced in significant future expectations. The success or failure of the upcoming Phase 3 clinical data will be a key watershed in determining the company’s long-term value. Investors chasing this “potential stock” need to be mindful of the gap between optimistic sentiment and clinical reality.
